Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) shared encouraging results from the pivotal Phase 2b HERIZON-BTC-01 trial, which assessed the efficacy of Zanidatamab, an investigational bispecific antibody developed on Zymeworks' Azymetric platform, in treating HER2-amplified biliary tract cancers. 

The data revealed significant clinical benefits, including an objective response rate (ORR) of 41.3%, a median duration of response (DOR) of 12.9 months, and a median progression-free survival (PFS) of 5.5 months, highlighting the potential of this treatment option for a cancer type currently lacking HER2-targeted therapies. 

On Friday, $JAZZ closed at $128.34 (-0.60%), while $ZYME closed at $8.67 (+2.12%). 

The Trade Desk, Inc. (Nasdaq: TTD), a global advertising technology company, received an upgrade from Equal-Weight to Overweight by Morgan Stanley, along with a raised price target from $60 to $90. 

With Friday's closing price of $74.24, Morgan Stanley's view suggests a potential upside of $15.76 (21.22%) for $TTD.

Kura Sushi USA, Inc. (Nasdaq: KRUS), a restaurant company offering Japanese cuisine, was initiated with a Neutral rating and a price target of $88 by Citigroup. 

$KRUS closed at $82.29 on Friday, implying a potential upside of $5.71 (6.94%) based on Citigroup's analysis.

Surgery Partners, Inc. (Nasdaq: SGRY), a leading operator of surgical facilities, was upgraded from Neutral to Buy by BofA Securities, with the price target raised from $42 to $45. 

With Friday's closing price of $39.78, the price target indicates a potential upside of $5.22 (13.11%) for $SGRY, according to BofA Securities' assessment. 

Please note that the potential upsides mentioned are derived from the price targets provided by brokerage firms, investment firms, or analysts. These assessments should be considered as their perspectives on the potential future performance of the stocks.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)